

Peiman Hematti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/400320/publications.pdf>

Version: 2024-02-01

132
papers

6,130
citations

101543

36
h-index

85541

71
g-index

148
all docs

148
docs citations

148
times ranked

9874
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	1.4	52
2	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 48.e1-48.e10.	1.2	18
3	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	5.2	25
4	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 335.e1-335.e17.	1.2	5
5	Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. <i>British Journal of Haematology</i> , 2022, 197, 326-338.	2.5	1
6	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1150-1163.	2.4	2
7	Pro-angiogenic Potential of Mesenchymal Stromal Cells Regulated by Matrix Stiffness and Anisotropy Mimicking Right Ventricles. <i>Biomacromolecules</i> , 2022, , .	5.4	2
8	A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF- κ B Activation and Drug Resistance. <i>Molecular Cancer Research</i> , 2022, 20, 1456-1466.	3.4	5
9	A biobehavioral intervention to enhance recovery following hematopoietic cell transplantation: Protocol for a feasibility and acceptability randomized control trial. <i>Contemporary Clinical Trials Communications</i> , 2022, 28, 100938.	1.1	1
10	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 681-693.	1.2	13
11	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 712.e1-712.e8.	1.2	3
12	Transplantation of T-cell receptor $\hat{\pm}/\hat{\iota}^2$ -depleted allogeneic bone marrow in nonhuman primates. <i>Experimental Hematology</i> , 2021, 93, 44-51.	0.4	3
13	Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. <i>International Journal of Cardiology</i> , 2021, 326, 131-138.	1.7	13
14	Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 158-166.	1.3	10
15	Cultured cardiac fibroblasts and myofibroblasts express Sushi Containing Domain 2 and assemble a unique fibronectin rich matrix. <i>Experimental Cell Research</i> , 2021, 399, 112489.	2.6	4
16	Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 503.e1-503.e8.	1.2	2
17	Sleep Disruption, Fatigue, and Depression as Predictors of 6-Year Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1405-1414.	6.3	13
18	Optimization of oxidative stress for mesenchymal stromal/stem cell engraftment, function and longevity. <i>Free Radical Biology and Medicine</i> , 2021, 167, 193-200.	2.9	13

#	ARTICLE	IF	CITATIONS
19	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.	1.2	13
20	Current status of myocardial restoration via the paracrine function of mesenchymal stromal cells. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 321, H112-H127.	3.2	4
21	Preclinical Evaluation of the Safety and Efficacy of Cryopreserved Bone Marrow Mesenchymal Stromal Cells for Corneal Repair. <i>Translational Vision Science and Technology</i> , 2021, 10, 3.	2.2	11
22	Tomotherapy Applied Total Lymphoid Irradiation and Allogeneic Hematopoietic Cell Transplantation Generates Mixed Chimerism in the Rhesus Macaque Model. <i>Radiation Research</i> , 2021, 196, 623-632.	1.5	6
23	Exosome-educated macrophages and exosomes differentially improve ligament healing. <i>Stem Cells</i> , 2021, 39, 55-61.	3.2	40
24	Hepatocellular Carcinoma Cells Are Protected From Immunolysis by Mesenchymal Stromal Cells Through Indoleamine 2,3 Dioxygenase. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 715905.	3.7	6
25	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 333-342.	2.0	30
26	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury—Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2020, 3, e1918668.	5.9	40
27	Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. <i>Leukemia Research</i> , 2020, 96, 106419.	0.8	11
28	Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1930-1936.	2.0	10
29	Discovering How Heme Controls Genome Function Through Heme-omics. <i>Cell Reports</i> , 2020, 31, 107832.	6.4	21
30	Different Human Immune Lineage Compositions Are Generated in Non-Conditioned NBSGW Mice Depending on HSPC Source. <i>Frontiers in Immunology</i> , 2020, 11, 573406.	4.8	19
31	Extracellular Vesicles as a Novel Therapeutic Option in Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1522-1531.	2.4	17
32	Use of MSCs and MSC-Educated Macrophages to Mitigate Hematopoietic Acute Radiation Syndrome. <i>Current Stem Cell Reports</i> , 2020, 6, 77-85.	1.6	7
33	Cardiac fibroblast derived matrix-educated macrophages express VEGF and IL-6, and recruit mesenchymal stromal cells. <i>Journal of Immunology and Regenerative Medicine</i> , 2020, 10, 100033.	0.4	8
34	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	5.2	263
35	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	1.6	36
36	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	5.2	14

#	ARTICLE	IF	CITATIONS
37	Early T Cell Activation Metrics Predict Graft-versus-Host Disease in a Humanized Mouse Model of Hematopoietic Stem Cell Transplantation. <i>Journal of Immunology</i> , 2020, 205, 272-281.	0.8	14
38	Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. <i>Blood</i> , 2020, 136, 137-139.	1.4	51
39	Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. <i>British Journal of Haematology</i> , 2020, 189, 1171-1181.	2.5	58
40	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1210-1217.	2.0	4
41	Endothelin-1 reduces catabolic activity of human mesenchymal stem/stromal cells during chondro- and osteo-lineage differentiation. <i>Biochemical and Biophysical Research Communications</i> , 2020, 529, 180-185.	2.1	4
42	Mesenchymal Stromal Cells and Exosomes: Progress and Challenges. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 665.	3.7	63
43	Reproducible Derivation and Expansion of Corneal Mesenchymal Stromal Cells for Therapeutic Applications. <i>Translational Vision Science and Technology</i> , 2020, 9, 26.	2.2	15
44	Therapeutic Effects of Lyophilized Conditioned-Medium Derived from Corneal Mesenchymal Stromal Cells on Corneal Epithelial Wound Healing. <i>Current Eye Research</i> , 2020, 45, 1490-1496.	1.5	15
45	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. <i>Blood Advances</i> , 2020, 4, 706-716.	5.2	11
46	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	5.2	34
47	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
48	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
49	Macrophages Educated with Exosomes from Primed Mesenchymal Stem Cells Treat Acute Radiation Syndrome by Promoting Hematopoietic Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2124-2133.	2.0	40
50	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
51	Bone Marrow Stromal Cells Transcriptionally Repress ESR1 but Cannot Overcome Constitutive ESR1 Mutant Activity. <i>Endocrinology</i> , 2019, 160, 2427-2440.	2.8	4
52	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
53	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1744-1755.	2.0	10
54	Potency Analysis of Mesenchymal Stromal Cells Using a Phospho-STAT Matrix Loop Analytical Approach. <i>Stem Cells</i> , 2019, 37, 1119-1125.	3.2	22

#	ARTICLE	IF	CITATIONS
55	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
56	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. <i>JAMA Pediatrics</i> , 2019, 173, e190081.	6.2	14
57	Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2558-2562.	1.3	13
58	Extracellular Vesicle-Educated Macrophages Promote Early Achilles Tendon Healing. <i>Stem Cells</i> , 2019, 37, 652-662.	3.2	132
59	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
60	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019, 3, 2836-2844.	5.2	38
61	TCR \hat{I}^2 +/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data. <i>Leukemia and Lymphoma</i> , 2019, 60, 598-609.	1.3	11
62	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 480-487.	2.0	10
63	Non-CVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 648-661.	2.4	14
64	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e145-e154.	2.0	16
65	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
66	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). <i>Blood</i> , 2019, 134, 764-764.	1.4	77
67	Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT). <i>Blood</i> , 2019, 134, 3088-3088.	1.4	0
68	Immunosuppression-Free Kidney Transplantation: Advancing New Treatments by Building on Our Past Foundations. <i>Wisconsin Medical Journal</i> , 2019, 118, 146-147.	0.3	0
69	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	2.4	1
70	Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function. <i>Stem Cells</i> , 2018, 36, 775-784.	3.2	49
71	Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity. <i>Journal of Immunotherapy</i> , 2018, 41, 213-223.	2.4	7
72	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7

#	ARTICLE	IF	CITATIONS
73	Bioengineering Solutions for Manufacturing Challenges in CAR T Cells. <i>Biotechnology Journal</i> , 2018, 13, 1700095.	3.5	56
74	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
75	Role of Extracellular Matrix in Cardiac Cellular Therapies. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1098, 173-188.	1.6	5
76	Effect of Human Corneal Mesenchymal Stromal Cell-derived Exosomes on Corneal Epithelial Wound Healing. , 2018, 59, 5194.		158
77	Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 2653-2658.	2.1	89
78	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.8	47
79	GATA/Heme Multi-omics Reveals a Trace Metal-Dependent Cellular Differentiation Mechanism. <i>Developmental Cell</i> , 2018, 46, 581-594.e4.	7.0	31
80	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. <i>Blood</i> , 2018, 132, 1015-1015.	1.4	2
81	Safety and efficacy of autologous serum eye drop for treatment of dry eyes in graft-versus-host disease. <i>Cutaneous and Ocular Toxicology</i> , 2017, 36, 152-156.	1.3	12
82	The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia. <i>Haematologica</i> , 2017, 102, 941-947.	3.5	15
83	Minocycline enhances the mesenchymal stromal/stem cell pro-healing phenotype in triple antimicrobial-loaded hydrogels. <i>Acta Biomaterialia</i> , 2017, 51, 184-196.	8.3	23
84	Extracellular Superoxide Dismutase Expression in Papillary Thyroid Cancer Mesenchymal Stem/Stromal Cells Modulates Cancer Cell Growth and Migration. <i>Scientific Reports</i> , 2017, 7, 41416.	3.3	31
85	Human Mesenchymal Stem Cell-“Educated Macrophages Are a Distinct High IL-6”Producing Subset that Confer Protection in Graft-versus-Host-Disease and Radiation Injury Models. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 897-905.	2.0	49
86	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1327-1334.	2.0	38
87	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79
88	Versican-Derived Matrikines Regulate Batf3-“Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. <i>Journal of Immunology</i> , 2017, 199, 1933-1941.	0.8	82
89	Collection of hematopoietic CD34 stem cells in rhesus macaques using Spectra Optia. <i>Journal of Clinical Apheresis</i> , 2017, 32, 288-294.	1.3	7
90	Minocycline modulates NF- κ B phosphorylation and enhances antimicrobial activity against <i>Staphylococcus aureus</i> in mesenchymal stromal/stem cells. <i>Stem Cell Research and Therapy</i> , 2017, 8, 171.	5.5	15

#	ARTICLE	IF	CITATIONS
91	Corneal Mesenchymal Stromal Cells Are Directly Antiangiogenic via PEDF and sFLT-1. , 2017, 58, 5507.		49
92	Local delivery of allogeneic bone marrow and adipose tissue-derived mesenchymal stromal cells for cutaneous wound healing in a porcine model. Journal of Tissue Engineering and Regenerative Medicine, 2016, 10, E90-E100.	2.7	39
93	Effects of Oxidative Stress on Mesenchymal Stem Cell Biology. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	4.0	227
94	Autologous Bone Marrow-Derived Mesenchymal Stem Cells Modulate Molecular Markers of Inflammation in Dogs with Cruciate Ligament Rupture. PLoS ONE, 2016, 11, e0159095.	2.5	36
95	Characterization of mesenchymal stromal cells: potency assay development. Transfusion, 2016, 56, 32S-5S.	1.6	28
96	Fibroblasts and Mesenchymal Stromal/Stem Cells Are Phenotypically Indistinguishable. Acta Haematologica, 2016, 136, 85-97.	1.4	169
97	Biodistribution and Clearance of Human Mesenchymal Stem Cells by Quantitative Three-Dimensional Cryo-Imaging After Intravenous Infusion in a Rat Lung Injury Model. Stem Cells Translational Medicine, 2016, 5, 1668-1675.	3.3	47
98	Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood, 2016, 128, 680-685.	1.4	119
99	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biology of Blood and Marrow Transplantation, 2016, 22, 520-527.	2.0	14
100	Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion. Cytotherapy, 2016, 18, 536-545.	0.7	9
101	Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies. Journal of Biological Chemistry, 2016, 291, 3268-3279.	3.4	75
102	International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 2016, 18, 151-159.	0.7	400
103	Single-molecule analysis reveals widespread structural variation in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7689-7694.	7.1	43
104	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunology Research, 2015, 3, 881-890.	3.4	24
105	Intravenous Followed by X-ray Fused with MRI-Guided Transendocardial Mesenchymal Stem Cell Injection Improves Contractility Reserve in a Swine Model of Myocardial Infarction. Journal of Cardiovascular Translational Research, 2015, 8, 438-448.	2.4	14
106	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biology of Blood and Marrow Transplantation, 2015, 21, 1830-1838.	2.0	12
107	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
108	Race and Ethnicity Influences Collection of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2015, 21, 165-171.	2.0	26

#	ARTICLE	IF	CITATIONS
109	A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. <i>Cytotherapy</i> , 2015, 17, 140-151.	0.7	83
110	TPL2 kinase regulates the inflammatory milieu of the myeloma niche. <i>Blood</i> , 2014, 123, 3305-3315.	1.4	89
111	MSC-Regulated MicroRNAs Converge on the Transcription Factor FOXP2 and Promote Breast Cancer Metastasis. <i>Cell Stem Cell</i> , 2014, 15, 762-774.	11.1	155
112	Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: lessons learned from a pilot randomized, double-blind, placebo-controlled trial. <i>Cytotherapy</i> , 2014, 16, 1720-1732.	0.7	41
113	No Impact of Lentiviral Transduction on Hematopoietic Stem/Progenitor Cell Telomere Length or Gene Expression in the Rhesus Macaque Model. <i>Molecular Therapy</i> , 2014, 22, 52-58.	8.2	4
114	Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model. <i>Cytotherapy</i> , 2014, 16, 1280-1293.	0.7	10
115	Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. <i>Cytotherapy</i> , 2014, 16, 1048-1058.	0.7	128
116	Potential role of mesenchymal stromal cells in pancreatic islet transplantation. <i>Transplantation Reviews</i> , 2013, 27, 21-29.	2.9	61
117	Brief Report: Mesenchymal Stromal Cell Atrophy in Coculture Increases Aggressiveness of Transformed Cells. <i>Stem Cells</i> , 2013, 31, 1218-1223.	3.2	21
118	Comparative Analysis of Adipose-Derived Mesenchymal Stem Cells Isolated From Abdominal and Breast Tissue. <i>Aesthetic Surgery Journal</i> , 2013, 33, 888-898.	1.6	32
119	The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?. <i>Blood</i> , 2013, 122, 5490-5490.	1.4	0
120	Biologic and immunomodulatory properties of mesenchymal stromal cells derived from human pancreatic islets. <i>Cytotherapy</i> , 2012, 14, 925-935.	0.7	27
121	Mesenchymal stromal cells and fibroblasts: a case of mistaken identity?. <i>Cytotherapy</i> , 2012, 14, 516-521.	0.7	137
122	Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. <i>British Journal of Haematology</i> , 2012, 158, 336-346.	2.5	100
123	Mesenchymal stromal cells are present in the heart and promote growth of adult stem cells in vitro. <i>Cytotherapy</i> , 2011, 13, 400-406.	0.7	25
124	Human Embryonic Stem Cell-Derived Mesenchymal Progenitors: An Overview. <i>Methods in Molecular Biology</i> , 2011, 690, 163-174.	0.9	37
125	Human embryonic stem cell-derived mesenchymal stromal cells. <i>Transfusion</i> , 2011, 51, 138S-144S.	1.6	18
126	Characterization of mesenchymal stem cells from human vocal fold fibroblasts. <i>Laryngoscope</i> , 2010, 120, 546-551.	2.0	74

#	ARTICLE	IF	CITATIONS
127	Mesenchymal stem cell-“educated macrophages: A novel type of alternatively activated macrophages. <i>Experimental Hematology</i> , 2009, 37, 1445-1453.	0.4	686
128	Mesenchymal stem cells in hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2009, 11, 503-515.	0.7	163
129	Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model. <i>Cytotherapy</i> , 2009, 11, 726-737.	0.7	63
130	Role of mesenchymal stromal cells in solid organ transplantation. <i>Transplantation Reviews</i> , 2008, 22, 262-273.	2.9	72
131	Derivation of SSEA4-/CD73+ Mesenchymal Stem Cells from Human Embryonic Stem Cells.. <i>Blood</i> , 2006, 108, 2579-2579.	1.4	0
132	Nonhuman primate embryonic stem cells as a preclinical model for hematopoietic and vascular repair. <i>Experimental Hematology</i> , 2005, 33, 980-986.	0.4	22